The New England Journal of Medicine April 03, 2003

Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction (EPHESUS)

Bertram Pitt, Willem Remme, Faiez Zannad, James Neaton, Felipe Martinez, Barbara Roniker, Richard Bittman, Steve Hurley, Jay Kleiman, Marjorie Gatlin

Source: View publication →

Bottom Line

In patients with left ventricular dysfunction and heart failure following an acute myocardial infarction, the addition of the selective aldosterone blocker eplerenone to optimal medical therapy significantly reduced both all-cause mortality and cardiovascular morbidity.

Key Findings

1. Over a mean follow-up of 16 months, all-cause mortality (a primary endpoint) was significantly reduced in the eplerenone group compared to the placebo group (14.4% [478 deaths] vs. 16.7% [554 deaths]; RR 0.85; 95% CI, 0.75-0.96; P=0.008).

2. The co-primary endpoint of cardiovascular death or hospitalization for cardiovascular events occurred significantly less frequently with eplerenone (26.7% vs. 30.0%; RR 0.87; 95% CI, 0.79-0.95; P=0.002).

3. Eplerenone therapy resulted in a 17% relative risk reduction in cardiovascular mortality (12.3% vs. 14.6%; RR 0.83; 95% CI, 0.72-0.94; P=0.005) and a 21% relative risk reduction in sudden death from cardiac causes (4.9% vs. 6.1%; RR 0.79; P=0.03).

4. The incidence of serious hyperkalemia (serum potassium ≥6.0 mmol/L) was significantly higher in the eplerenone group (5.5% vs. 3.9%; P=0.002).

5. The incidence of serious hypokalemia (<3.5 mmol/L) was significantly lower in the eplerenone group compared to placebo (8.4% vs. 13.1%; P<0.001).

Study Design

Design

RCT

Double-Blind

Sample

6,632

Patients

Duration

16 mo

Median

Setting

Multicenter, global

Population Patients 3 to 14 days post-acute myocardial infarction with left ventricular ejection fraction ≤40% and clinical evidence of heart failure (or diabetes).

Intervention Eplerenone 25 mg daily initially, titrated up to a target of 50 mg daily, added to standard medical therapy.

Comparator Matching placebo added to standard medical therapy.

Outcome Time to death from any cause, and time to death from cardiovascular causes or hospitalization for cardiovascular events.

Study Limitations

• The follow-up period was relatively short (mean 16 months), limiting the evaluation of eplerenone's very long-term safety and efficacy in this population.

• The required exclusion of patients with a baseline serum creatinine >2.5 mg/dL or serum potassium >5.0 mmol/L restricts the generalizability of the findings in patients with advanced chronic kidney disease.

• The significant increase in serious hyperkalemia necessitates stringent laboratory monitoring, which can be challenging to maintain in real-world clinical practice.

• The trial was conducted before the advent of current modern foundational therapies, such as ARNI and SGLT2 inhibitors, which might influence the absolute magnitude of eplerenone's benefit today.

Clinical Significance

EPHESUS was a landmark trial that successfully expanded the indication for mineralocorticoid receptor antagonists (MRAs) to the immediate post-myocardial infarction setting. It proved that early administration of eplerenone—a selective MRA with minimal anti-androgenic side effects—improves survival and reduces hospitalizations in patients with post-MI left ventricular dysfunction and heart failure, establishing it as a foundational pillar in guideline-directed medical therapy.

Historical Context

The 1999 RALES trial had previously established the profound mortality benefit of spironolactone (a non-selective MRA) in severe chronic heart failure. However, spironolactone caused frequent endocrine side effects like gynecomastia, and the role of MRAs in the acute post-myocardial infarction period to prevent adverse ventricular remodeling remained uncertain. EPHESUS was designed to address this gap, evaluating the highly selective agent eplerenone specifically during the high-risk window (3 to 14 days) following an acute MI complicated by heart failure.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

How does the mechanism of eplerenone differ from spironolactone, and why is this clinically relevant in terms of side effect profiles?

Key Response

Eplerenone is a selective mineralocorticoid receptor antagonist. Unlike spironolactone, it has very low affinity for androgen and progesterone receptors, significantly reducing the incidence of gynecomastia, breast pain, and menstrual irregularities, thereby improving patient compliance.

Resident

A patient 5 days post-MI with an LVEF of 35% and pulmonary crackles is being prepped for discharge on lisinopril and metoprolol. Based on EPHESUS, why should eplerenone be added to this regimen, and what lab parameter requires strict monitoring?

Key Response

EPHESUS demonstrated that adding eplerenone to standard therapy in post-MI patients with LVEF <=40% and HF symptoms reduces all-cause mortality. Potassium and creatinine must be strictly monitored because MRAs increase the risk of severe hyperkalemia, particularly when combined with ACE inhibitors.

Fellow

The EPHESUS trial included patients with diabetes and reduced LVEF even in the absence of clinical signs of heart failure. What is the pathophysiological rationale for this inclusion, and how does aldosterone blockade specifically benefit the diabetic post-MI myocardium?

Key Response

Diabetic patients are at an elevated risk for extensive interstitial fibrosis, endothelial dysfunction, and adverse ventricular remodeling post-MI. Aldosterone promotes collagen deposition and oxidative stress; selective blockade mitigates this profibrotic cascade, which is notably accelerated in the diabetic milieu.

Attending

How did the EPHESUS trial shift the paradigm of timing for neurohormonal blockade post-MI compared to older heart failure trials, and how do you weigh the early mortality benefit against the risk of acute hyperkalemia during the vulnerable post-discharge phase?

Key Response

While earlier trials studied chronic severe HF, EPHESUS proved that early initiation (3-14 days post-MI) of an MRA blunts acute adverse remodeling and significantly reduces sudden cardiac death within the first 30 days. This early mortality benefit mandates proactive initiation prior to discharge, rather than waiting for outpatient follow-up, provided renal function and potassium are stable.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

The trial utilized a dual primary endpoint: time to death from any cause, and time to cardiovascular death or cardiovascular hospitalization. How does the choice of dual primary endpoints affect statistical power and alpha spending, and how must investigators account for this in their study design?

Key Response

Dual primary endpoints inflate the risk of Type I error (false positives). To maintain the overall trial alpha at 0.05, investigators must use alpha-allocation strategies (e.g., splitting the alpha, such as 0.04 and 0.01). This necessitates larger sample sizes to ensure adequate statistical power for evaluating both endpoints independently.

Journal Editor

Over 85% of EPHESUS patients were on ACE inhibitors and 75% on beta-blockers. Given that contemporary post-MI management incorporates early revascularization, ARNIs, and SGLT2 inhibitors, how does the background therapy in this 2003 trial challenge the external validity and anticipated effect size of eplerenone in today's clinical landscape?

Key Response

A critical reviewer would flag that background medical and interventional therapies have evolved drastically. The absolute risk reduction observed in EPHESUS might be attenuated in a modern cohort universally treated with early PCI, ARNIs, and SGLT2 inhibitors, raising questions about current cost-benefit ratios and polypharmacy risks.

Guideline Committee

How do the EPHESUS findings directly inform the ACC/AHA and ESC Class I recommendations for MRA use in post-MI patients, and what specific clinical criteria dictate this guideline-directed medical therapy?

Key Response

EPHESUS provides Level of Evidence A for the Class I recommendation that an MRA be administered to post-MI patients with an LVEF <=40% who have symptomatic HF or diabetes mellitus. Current guidelines explicitly adopt the EPHESUS inclusion criteria to define this target population, while emphasizing the necessity of monitoring potassium and renal function to prevent adverse events.

Clinical Landscape

Noteworthy Related Trials

1999

RALES Trial

n = 1,663 · NEJM

Tested

Spironolactone 25mg daily

Population

Patients with severe heart failure (NYHA class III-IV) and reduced ejection fraction

Comparator

Placebo

Endpoint

All-cause mortality

Key result: Spironolactone reduced the risk of death by 30 percent compared to placebo.

2003

VALIANT Trial

n = 14,703 · NEJM

Tested

Valsartan

Population

Patients with acute myocardial infarction complicated by heart failure or left ventricular dysfunction

Comparator

Captopril

Endpoint

All-cause mortality

Key result: Valsartan was non-inferior to captopril in reducing mortality post-MI, establishing an alternative to ACE inhibitors.

2010

EMPHASIS-HF Trial

n = 2,737 · NEJM

Tested

Eplerenone up to 50mg daily

Population

Patients with mild heart failure (NYHA class II) and reduced ejection fraction

Comparator

Placebo

Endpoint

Composite of cardiovascular death or hospitalization for heart failure

Key result: Eplerenone significantly reduced the risk of cardiovascular death or heart failure hospitalization by 37 percent.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis